Complement insufficiency limits efficacy in a xenograft model of hyperacute rejection for cancer therapy

Ahmad SR, Lidington EA, Ohta R, Okada N, Robson MG, Davies KA, Leitges M, Harris CL, Haskard DO, Mason JC (2003) Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition. Immunology 110:258–268 Deriy L, Ogawa H, Gao GP, Galili U (2005) In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene. Cancer Gene Ther 12:528–539 Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, Vidal JM, van de Vorstenbosch C (2001) A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21:15–23 Fisicaro N, Aminian A, Hinchliffe SJ, Morgan BP, Pearse MJ, D’Apice AJ, Cowan PJ (2000) The pig analogue of CD59 protects transgenic mouse hearts from injury by human complement. Transplantation 70:963–968 Galili U, Clark MR, Shohet SB, Buehler J, Macher BA (1987) Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1–3Gal epitope in primates. Proc Natl Acad Sci USA 84:1369–1373 Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA (1988) Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 263:17755–17762 Ingram N, Porter CD (2005) Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy. Gene Ther 12:1058–1069 Jager U, Takeuchi Y, Porter C (1999) Induction of complement attack on human cells by Gal(alpha1,3)Gal xenoantigen expression as a gene therapy approach to cancer. Gene Ther 6:1073–1083 Larkin JMG, Norsworthy PJ, A’Hern RJ, Eisen TG, Gore ME, Porter CD (2006) Anti-aGal-dependent complement-mediated cytotoxicity in metastatic melanoma. Melanoma Res 16:157–163 LaTemple DC, Galili U (1998) Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase. Xenotransplantation 5:191–196 LaTemple DC, Abrams JT, Zhang SY, Galili U (1999) Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. Cancer Res 59:3417–3423 Lunardi-Iskandar Y, Bryant JL, Zeman RA, Lam VH, Samaniego F, Besnier JM, Hermans P, Thierry AR, Gill P, Gallo RC (1995) Tumorigenesis and metastasis of neoplastic Kaposi’s sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 375:64–68 Mason JC, Lidington EA, Yarwood H, Lublin DM, Haskard DO (2001) Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum 44:138–150 Mavria G, Jager U, Porter CD (2000) Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Ther 7:368–376 Mavria G, Porter CD (2001) Reduced growth in response to ganciclovir treatment of subcutaneous xenografts expressing HSV-tk in the vascular compartment. Gene Ther 8:913–920 Mavria G, Harrington KJ, Marshall CJ, Porter CD (2005) In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy. J Gene Med 7:263–275 McKenzie IF, Li YQ, Patton K, Thall AD, Sandrin MS (1998) A murine model of antibody-mediated hyperacute rejection by galactose-alpha(1,3)galactose antibodies in Gal o/o mice. Transplantation 66:754–763 McMorrow IM, Comrack CA, Sachs DH, DerSimonian H (1997) Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(alpha1,3)Galactose epitope. Transplantation 64:501–510 Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH (1991) Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 52:214–220 Richardson TB, Kaspers J, Porter CD (2004) Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity. Gene Ther 11:775–783 Rollins SA, Zhao J, Ninomiya H, Sims PJ (1991) Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol 146:2345–2351 Rossi GR, Mautino MR, Unfer RC, Seregina TM, Vahanian N, Link CJ (2005) Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes. Cancer Res 65:10555–10561 Rossi GR, Unfer RC, Seregina T, Link CJ (2005) Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopes. Cancer Immunol Immunother 54:999–1009 Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IF (1993) Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1–3)Gal epitopes. Proc Natl Acad Sci USA 90:11391–11395 Schroeder C, Allan JS, Nguyen BN, Wu G, Zhang T, Azimzadeh AM, Madsen JC, Schuurman HJ, Sachs DH, Pierson RN 3rd (2005) Hyperacute rejection is attenuated in GalT knockout swine lungs perfused ex vivo with human blood. Transplant Proc 37:512–513 Thall AD, Maly P, Lowe JB (1995) Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem 270:21437–21440 Williams RL, Courtneidge SA, Wagner EF (1988) Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene. Cell 52:121–131